Member of Faculty Lab:

  • Jeffrey Johnson
head shot image

Delinda Johnson, PhD

Senior Scientist


  • PhD Molecular and Environmental Toxicology (Neurotoxicology) - University of Wisconsin-Madison
  • BS University of Wisconsin-Madison
Highlighted Publications:

•      Hoang TT, Johnson DA, Raines RT, Johnson J1 (2019). Angiogenin activates the astrocytic Nrf2/ARE pathway and thereby protects murine neurons from oxidative stress. J Biol Chem. 2019 Aug 20. pii: jbc.RA119.008491. doi: 10.1074/jbc.RA119.008491. [Epub ahead of print]

•      Lee LY, Harberg C, Matkowskyj KA, Cook S, Roenneburg D, Werner S, Johnson DA, Johnson JA, Foley DP (2016). Cell-specific overactivation of nuclear erythroid 2 p45-related factor 2-mediated gene expression in myeloid cells decreases hepatic ischemia/reperfusion injury.  Liver Transpl. 2016 Aug;22(8):1115-28. doi: 10.1002/lt.24473.

•      Johnson DA, Johnson JA (2015). Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radical Biology of Medicine. 2015 Aug 14. pii: S0891-5849(15)00471-2.

•      Joshi G, Gan KA, Johnson DA, Johnson JA (2015). Increased Alzheimer's disease-like pathology in the APP/ PS1ΔE9 mouse model lacking Nrf2 through modulation of autophagy. Neurobiol Aging. 2015 Fe 36(2):664-79. doi: 10.1016/j.neurobiolaging.2014.09.004. Epub 2014 Sep 6.

•     Kulkarni SR, Donepudi AC, Xu J, Wei W, Cheng QC, Driscoll MV, Johnson DA, Johnson JA, Li X, Slitt AL (2014).  Fasting induces nuclear factor E2-related factor 2 and ATP-binding Cassette transporters via protein kinase A and Sirtuin-1 in mouse and human.  Antioxid Redox Signal. 2014 Jan 1;20(1):15-30.

•     Swanson CR, Du E, Johnson DA, Johnson JA, Emborg ME (2013). Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.  PPAR Res. 2013;2013:582809.

•     Marcelo R. Vargas, Neal C. Burton, Li Gan, Delinda A. Johnson, Matthias Schaafer, Sabine Werner, Jeffrey A. Johnson (2013). Absence of Nrf2 or Its Selective Overexpression in Neurons and Muscle Does Not Affect Survival in ALSLinked Mutant hSOD1 Mouse Models. PLOS ONE February 2013 | Volume 8 | Issue 2 | e56625.

•     Béraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, Federoff HJ, Shimoji M, Mhyre TR, Maguire-Zeiss KA (2013). Microglial Activation and Antioxidant Responses Induced by the Parkinson's Disease Protein -Synuclein. J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117.  Mar Drugs. 2013 Dec 16;11(12):5089-99. doi: 10.3390/md11125089.

•     Wyche TP, Standiford M, Hou Y, Braun D, Johnson DA, Johnson JA, Bugni TS (2013).  Activation of the Nuclear Factor E2-Related Factor 2 Pathway by Novel Natural Products Halomadurones A-D and a Synthetic Analogue. Mar Drugs. 2013 Dec 16;11(12):5089-99.

•     Fischedick JT1, Standiford M, Johnson DA, Johnson JA (2013).  Structure Activity Relationship of Phenolic Diterpenes from Salvia Officinalis as Activators of the Nuclear Factor E2-Related Factor 2 Pathway. Bioorg Med Chem. 2013 May 1;21(9):2618-22.

•     Gan L, Vargas MR, Johnson DA, Johnson JA (2012). Astrocyte-specific Overexpression of Nrf2 Delays Motor Pathology and Synuclein Aggregation throughout the CNS in the Alpha-synuclein Mutant (A53T) Mouse Model. J Neurosci. 2012 Dec 5;32(49):17775-87.

•     Williamson TP, Amirahmadi S, Joshi G, Kaludov NK, Martinov MN, Johnson DA, Johnson JA. (2012). Discovery of potent, novel Nrf2 inducers via quantum modeling, virtual screening and in vitro experimental validation. Chemical Biology and Drug Design, 80(6):810-20.

•     Lapash Daniels CM, Austin EV, Rockney DE, Jacka EM, Hagemann TL, Johnson DA, Johnson JA, Messing A (2012). Beneficial effects of nrf2 overexpression in a mouse model of alexander disease. J. Neurosci. 32(31):10507-15.

•     Williamson TP, Johnson DA, Johnson JA. (2012). Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology, 33(3):272-9.  Planta Med. 2012 Nov;78(16):1725-30.

•     Fischedick JT, Standiford M, Johnson DA, De Vos RC, Todorovi? S, Banjanac T, Verpoorte R, Johnson JA (2012). Activation of antioxidant response element in mouse primary cortical cultures with sesquiterpene lactones isolated from Tanacetum parthenium.

•     Vargas MR., Johnson DA, Johnson JA. (2011). Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1G93A mice model. Neurobiol Dis. 43(3):543-51.

•     Gan L, Johnson DA, Johnson JA. (2010). Keap1-Nrf2 Activation in the Presence and Absence of DJ-1. Eur. J. Neurosci. 31(6):967-77.

•     Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA (2010). The Absence of the Pro-Antioxidant Transcription Factor Nrf2 Exacerbates Experimental Autoimmune Encephalomyelitis. Toxicol. Sci. 114(2):237-46.   Highlighted Paper.

•     Son TG, Camandola S, Arumugam TV, Cutler RG, Telljohann RS, Mughal MR, Moore TA, Yu QS, Johnson DA, Johnson JA, Greig NH, Mattson MP. (2009). Plumbagin, a Novel Nrf2/ARE Activator, Protects Against Cerebral Ischemia. J Neurochem. 112(5):1316-26.

•     Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, and J.A. Johnson (2009). Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A. 106(8):2933-8.

•     Yates, MS, Tauchi, M, Katsuoka, F, Flanders, KC, Liby, KT, Honda T, Gribble, GW, Johnson, DA,   Johnson, JA, Burton, NC, Guilarte, TR, Yamamoto, M, Sporn, MB, and TW Kensler (2007).  Pharmacodynamic Characterization of Chemopreventive Triterpenoids as Exceptionally Potent   Inducers of Nrf2-Regulated Genes. Mol Cancer Ther. 2007 Jan;6(1):154-62.

•     Hagemann TL, Gaeta SA, Smith MA, Johnson DA, Johnson JA, Messing A (2005).  Gene expression analysis in mice with elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and neuronal dysfunction.  Hum Mol Genet. 2005 Aug 15;14(16):2443-58.

•     Jakel RJ, Kern JT, Johnson DA, Johnson JA (2005).  Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro.  Toxicol Sci. 2005 Sep; 87(1):176-86.

•     Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA (2005).  Nrf2, a multi-organ protector?  FASEB J. 2005 Jul;19(9):1061-6.

•     Li J, Spletter ML, Johnson DA, Wright LS, Svendsen CN, Johnson JA (2005).  Rotenone-induced caspase 9/3-independent and -dependent cell death in undifferentiated and differentiated human neural stem cells.  J Neurochem. 2005 Fe 92(3):462-76.

•     Calkins, MJ, Jakel, RJ, Johnson, DA, Chan K, Kan YW and JA Johnson (2005). Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc. Natl. Acad. Sci. USA. 102(1):244-9.

•     Kraft, AD, Johnson, DA and JA Johnson (2004). Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci. 24(5):1101-12.

•     Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH. Coordinate regulation of glutathione biosynthesis and release by nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci.2003;23:3394-3406.

•     Johnson, DA, Xu, W, Andrews, GK and JA Johnson (2002). Activation of the antioxidant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J. Neurochem. 81(6):1233-1241.

•     Gibson DF, Johnson DA, Langan-Fahey SM, Lababidi MK, Wolberg WH, Jordan VC (1993). The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model. Breast Cancer Res Treat. 1993 Sep 27(3):283-7.

•     Gibson DF, Johnson DA, Goldstein D, Langan-Fahey SM, Borden EC, Jordan VC (1993). Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Res Treat. 1993;25(2):141-50.

•     Iino Y, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, Thompson ME, Jordan VC (1991). Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer. 1991 Dec;64(6):1019-24.

•    Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC (1991). Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991 Jan-Fe 19(1):36-43.

•    Robinson SP, Mauel DA, Jordan VC (1988).  Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model.  Eur J Cancer Clin Oncol. 1988 Dec;24(12):1817-21.